Supernus Pharmaceuticals(SUPN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SUPN Supernus Pharmaceuticals

Trading 01-26 14:47:47 EST

49.57

+1.32

+2.74%

High49.67	Low48.07	Vol403.21K
Open48.07	D1 Closing48.25	Amplitude3.32%
Mkt Cap2.84B	Tradable Cap2.42B	Total Shares57.34M
T/O19.64M	T/O Rate0.82%	Tradable Shares48.90M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SUPN","market":"US","secType":"STK","nameCN":"Supernus Pharmaceuticals","latestPrice":49.57,"timestamp":1769456864334,"preClose":48.25,"halted":0,"volume":403210,"delay":0,"changeRate":0.02735751295336788,"floatShares":48898547,"shares":57339350,"eps":-0.341572,"marketStatus":"Trading","change":1.32,"latestTime":"01-26 14:47:47 EST","open":48.07,"high":49.67,"low":48.07,"amount":19635399.617,"amplitude":0.033161,"askPrice":49.62,"askSize":189,"bidPrice":49.51,"bidSize":624,"shortable":3,"etf":0,"ttmEps":-0.341572,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1769461200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1335844800000,"exchange":"NASDAQ","adjPreClose":48.25,"preHourTrading":{"tag":"盘前","latestPrice":48.3,"preClose":48.25,"latestTime":"09:18 EST","volume":1375,"amount":66277.5135,"timestamp":1769437087611,"change":0.05,"changeRate":0.001036,"amplitude":0.031088},"postHourTrading":{"tag":"盘后","latestPrice":48.25,"preClose":48.25,"latestTime":"17:14 EST","volume":16541,"amount":798100.72,"timestamp":1769206478774,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.705344,"impliedVol":0.4019,"impliedVolPercentile":0.8446},"requestUrl":"/m/hq/s/SUPN/wiki","defaultTab":"wiki","newsList":[{"id":"2603037935","title":"Crawford & Company Sets $475,000 Salary and New Incentives for US Operations CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2603037935","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603037935?lang=en_us&edition=fundamental","pubTime":"2026-01-16 05:31","pubTimestamp":1768512686,"startTime":"0","endTime":"0","summary":"Crawford & Company has announced a new Executive Employment Agreement for Michael J. Hoberman following his promotion to CEO - US Operations, effective January 1, 2026. Under the new agreement, Hoberman will receive an annual base salary of $475,000. He is also eligible for an annual bonus under the Short Term Incentive Plan, with a target payout of 57.5% of his base salary for 2026. Additionally, he will receive Long Term Incentive Plan awards at a target value of $550,000 for 2026 and a Sales Incentive Payment equal to 0.5% of quarterly billed US service fees for the first 24 months of each sale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crawford & Company published the original content used to generate this news brief via EDGAR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL8yCncJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SUPN","BK4007"],"gpt_icon":0},{"id":"2601807337","title":"Biopharma Sector Enters 2026 With Clearer Outlook, Key Catalysts, BofA Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2601807337","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601807337?lang=en_us&edition=fundamental","pubTime":"2026-01-08 00:21","pubTimestamp":1767802874,"startTime":"0","endTime":"0","summary":"The biopharmaceutical sector is entering 2026 with improved visibility as companies like Amphastar (AMPH), Catalyst (CPRX), and Supernus (SUPN) face key execution and growth catalysts, BofA Securities","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4007","CPRX","IE0034390439.USD","SUPN","BK4557","IE00B19Z6F94.USD","BK4139","BK4585","AMPH"],"gpt_icon":0},{"id":"2593527458","title":"Supernus Pharmaceuticals SVP Frank Mottola Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593527458","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593527458?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:05","pubTimestamp":1766437517,"startTime":"0","endTime":"0","summary":"Frank Mottola, SVP, Chief Technical Operations Officer of Supernus Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Supernus Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL8BGhz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Supernus Pharmaceuticals SVP Frank Mottola Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SUPN"],"gpt_icon":0},{"id":"2592419746","title":"Supernus Pharmaceuticals SVP Padmanabh Bhatt Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592419746","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592419746?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:06","pubTimestamp":1766178375,"startTime":"0","endTime":"0","summary":"Padmanabh P. Bhatt, Senior Vice President of IP and Chief Scientific Officer at Supernus Pharmaceuticals Inc., reported a disposal of common shares of Supernus Pharmaceuticals Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Supernus Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL9QmDPF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Supernus Pharmaceuticals SVP Padmanabh Bhatt Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SUPN","BK4007"],"gpt_icon":0},{"id":"2592194084","title":"Supernus Pharmaceuticals on Pace for Longest Winning Streak Since July 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2592194084","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592194084?lang=en_us&edition=fundamental","pubTime":"2025-12-20 03:52","pubTimestamp":1766173920,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals, Inc.  is currently at $51.78, up $2.50 or 5.07%. --Would be highest close since Nov. 4, 2025, when it closed at $57.00. --On pace for largest percent increase since Aug. 6, 2025, when it rose 13.08%. --Currently up eight consecutive days; up 14% over this period. --Longest winning streak since July 19, 2024, when it rose for 12 straight trading days. --Up 9.80% this week; best weekly performance since the week ending Aug. 8, 2025, when it rose 16.12%. --Up 43.2% year-to-date; on pace for best year since 2017, when it rose 57.82%. --Down 13.48% from its all-time closing high of $59.85 on June 29, 2018. --Up 46.15% from 52 weeks ago , when it closed at $35.43. --Up 70.95% from its 52-week closing low of $30.29 on April 21, 2025. --Traded as high as $52.11; highest intraday level since Nov. 4, 2025, when it hit $57.40. --Up 5.74% at today's intraday high; largest intraday percent increase since Oct. 9, 2025, when it rose as much as 7.87%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SUPN","BK4007"],"gpt_icon":0},{"id":"2590147341","title":"Supernus Pharmaceuticals Says Postpartum Depression Treatment Receives Authorization From Health Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2590147341","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590147341?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:43","pubTimestamp":1765287808,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals (SUPN) said Tuesday that Health Canada issued a notice of compliance for Zurzuvae (zuranolone) for the treatment of moderate or severe postpartum depression in adults followin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SUPN","BK4007"],"gpt_icon":0},{"id":"2588021442","title":"Supernus Pharmaceuticals to Present at Bank of America Securities CNS Therapeutics Virtual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588021442","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588021442?lang=en_us&edition=fundamental","pubTime":"2025-12-04 05:05","pubTimestamp":1764795911,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals Inc. will participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference, with President and CEO Jack A. Khattar scheduled to present on Monday, December 8, 2025, at 3:20 p.m. ET. A live audio webcast of the presentation will be available on the Supernus Pharmaceuticals website, with an archived replay accessible for 60 days following the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Supernus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL4Gqhwd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU1496350171.SGD","IE0002270589.USD","LU0648001328.SGD","LU1035773651.USD","LU0648000940.SGD","IE0034235188.USD","LU0128525689.USD","LU0310800965.SGD","LU1506573853.SGD","IE00BBT3K403.USD","IE00BZ1G4Q59.USD","BK4585","BK4534","LU0314106906.USD","LU0130518102.USD","LU0971096721.USD","LU1201861249.SGD","BK4553","IE00B3QW5Z07.USD","LU0208291251.USD","LU1267930227.SGD","LU0477156953.USD","LU1880398471.USD","LU0130102774.USD","LU0070302665.USD","LU1496350502.SGD","LU1074936037.SGD","LU0203347892.USD","LU1280957306.USD","IE00B7SZLL34.SGD","IE00BKVL7J92.USD","IE0001KFT4U8.USD","IE00B64PRP62.GBP","SUPN","LU0477156797.USD","IE00BFXG1179.USD","BAC","BK4504","IE00BLSP4452.SGD","LU0098860793.USD","LU0980610538.SGD","LU1894683348.USD","LU0683600562.USD","BK4007","LU1804176565.USD","NDAQ","LU0256863811.USD","LU1668664300.SGD","LU0321505868.SGD"],"gpt_icon":0},{"id":"2585125200","title":"Supernus Pharmaceuticals to Join Piper Sandler Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2585125200","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585125200?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:06","pubTimestamp":1763759170,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals Inc. will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The event will feature Jack A. Khattar, President and CEO of Supernus Pharmaceuticals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Supernus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on November 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDLbP11VM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIPR","IE00B64PRP62.GBP","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","BK4127","IE00B3QW5Z07.USD","LU2210150020.SGD","SUPN","LU0314104364.USD","BK4007","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2583650560","title":"Supernus Pharmaceuticals (SUPN): Assessing Valuation After Q3 Revenue Growth and Raised Guidance Despite Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2583650560","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583650560?lang=en_us&edition=fundamental","pubTime":"2025-11-16 07:16","pubTimestamp":1763248590,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals (SUPN) just posted its third quarter earnings, showing higher revenue but a significant move from last year's profit to a net loss. At the same time, the company raised its outlook for full-year revenue and operating loss. This signals increased confidence from management for the remainder of 2025.\nSee our latest analysis for Supernus Pharmaceuticals.\nShares of Supernus Pharmaceuticals have shown solid momentum this year, with a year-to-date share price return of...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/supernus-pharmaceuticals-supn-assessing-valuation-after-q3-r","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/supernus-pharmaceuticals-supn-assessing-valuation-after-q3-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SUPN"],"gpt_icon":0},{"id":"2582487895","title":"Supernus Pharmaceuticals (SUPN) Is Down 17.4% After Raising 2025 Guidance Amid Margin and Supply Pressures – Has the Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2582487895","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582487895?lang=en_us&edition=fundamental","pubTime":"2025-11-10 17:22","pubTimestamp":1762766576,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals recently reported past third-quarter results with revenue and earnings exceeding expectations, driven by strong sales of its neurology products Qelbree, GOCOVRI, and the launch of ONAPGO, while also raising its 2025 revenue guidance to a range of US$685 million to US$705 million.\nThe company's performance was powered by increased demand for new treatments but was tempered by higher acquisition-related expenses, operating margin pressures, and temporary supply...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/supernus-pharmaceuticals-supn-is-down-174-after-raising-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/supernus-pharmaceuticals-supn-is-down-174-after-raising-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","SUPN"],"gpt_icon":0},{"id":"2582886236","title":"Supernus Pharmaceuticals (SUPN): Evaluating Valuation After Strong Q3 Growth, Margin Pressure, and Updated 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2582886236","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582886236?lang=en_us&edition=fundamental","pubTime":"2025-11-09 05:28","pubTimestamp":1762637315,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals (SUPN) saw a jump in third-quarter sales, fueled by the momentum of Qelbree, GOCOVRI, and the launch of ONAPGO. The company boosted its full-year 2025 revenue outlook following these results.\nSee our latest analysis for Supernus Pharmaceuticals.\nDespite impressive third-quarter results and a boosted product pipeline, Supernus Pharmaceuticals shares experienced a steep pullback after the recent earnings announcement. The 7-day share price return dropped 16.5%,...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/supernus-pharmaceuticals-supn-evaluating-valuation-after-str","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/supernus-pharmaceuticals-supn-evaluating-valuation-after-str","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SUPN","BK4007"],"gpt_icon":0},{"id":"2581722937","title":"Supernus Pharmaceuticals Down Nearly 18%, On Track for Largest Percent Decrease Since November 2019 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722937","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722937?lang=en_us&edition=fundamental","pubTime":"2025-11-06 00:52","pubTimestamp":1762361520,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals, Inc.  is currently at $46.80, down $10.20 or 17.89%. --Would be lowest close since Sept. 19, 2025, when it closed at $46.04. --On pace for largest percent decrease since Nov. 6, 2019, when it fell 31.58%. --Up 29.44% year-to-date; on pace for best year since 2017, when it rose 57.82%. --Down 21.8% from its all-time closing high of $59.85 on June 29, 2018. --Up 23.99% from 52 weeks ago , when it closed at $37.75. --Traded as low as $43.11; lowest intraday level since Aug. 21, 2025, when it hit $42.67. --Down 24.37% at today's intraday low; largest intraday percent decrease since Nov. 6, 2019, when it fell as much as 33.57%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SUPN","BK4007"],"gpt_icon":0},{"id":"1186230456","title":"Stock Track | Supernus Pharmaceuticals Plummets 21.58% as Q3 Earnings Show Significant Loss Despite Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1186230456","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186230456?lang=en_us&edition=fundamental","pubTime":"2025-11-05 22:44","pubTimestamp":1762353898,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals (NASDAQ: SUPN) saw its stock price plummet 21.58% in early trading on Wednesday, following the release of its third-quarter earnings report. The sharp decline comes as...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SUPN"],"gpt_icon":0},{"id":"1148440565","title":"Stock Track | Supernus Pharmaceuticals Plunges 12.25% Pre-market Following Q3 Loss Despite Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1148440565","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148440565?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:32","pubTimestamp":1762345949,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals (NASDAQ: SUPN) saw its stock price plummet 12.25% in pre-market trading on Wednesday, following the release of its third-quarter earnings report. The significant drop comes...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SUPN"],"gpt_icon":0},{"id":"2581671176","title":"Supernus Pharmaceuticals Reports Strong Q3 2025 Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2581671176","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581671176?lang=en_us&edition=fundamental","pubTime":"2025-11-05 13:15","pubTimestamp":1762319753,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals ( ($SUPN) ) has released its Q3 earnings. Here is a breakdown of the information Supernus Pharmaceuticals presented to its...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/supernus-pharmaceuticals-reports-strong-q3-2025-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/supernus-pharmaceuticals-reports-strong-q3-2025-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SUPN","BK4007"],"gpt_icon":0},{"id":"1109320070","title":"Stock Track | Supernus Pharmaceuticals Plunges 11.82% After Hours Despite Q3 Revenue Beat, Weighed Down by Operating Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1109320070","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109320070?lang=en_us&edition=fundamental","pubTime":"2025-11-05 10:29","pubTimestamp":1762309764,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals (NASDAQ: SUPN) saw its stock price plummet 11.82% in after-hours trading on Tuesday, despite reporting third-quarter revenues that exceeded analyst expectations. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SUPN"],"gpt_icon":0},{"id":"2581179797","title":"Supernus Pharmaceuticals: Strong Product Performance and Strategic Management Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581179797","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581179797?lang=en_us&edition=fundamental","pubTime":"2025-11-05 09:35","pubTimestamp":1762306512,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Stacy Ku from TD Cowen maintaine...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/supernus-pharmaceuticals-strong-product-performance-and-strategic-management-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/supernus-pharmaceuticals-strong-product-performance-and-strategic-management-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SUPN"],"gpt_icon":0},{"id":"1178412502","title":"Stock Track | Supernus Pharmaceuticals Plunges 12.28% After-Hours Despite Beating Q3 Estimates, Reports Operating Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1178412502","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178412502?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:40","pubTimestamp":1762292405,"startTime":"0","endTime":"0","summary":"Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) tumbled 12.28% in after-hours trading on Tuesday, despite the company reporting better-than-expected third-quarter results. The sharp decline reflects...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SUPN"],"gpt_icon":0},{"id":"1155637272","title":"Stock Track | Supernus Pharmaceuticals Plunges 12.28% After-Hours Despite Beating Q3 Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=1155637272","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155637272?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:40","pubTimestamp":1762292401,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals (NASDAQ: SUPN) saw its stock price plummet 12.28% in after-hours trading on Tuesday, despite reporting third-quarter earnings that beat analyst expectations. The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SUPN"],"gpt_icon":0},{"id":"2581769359","title":"BRIEF-Supernus Pharmaceuticals Q3 Product Sales USD 168.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581769359","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581769359?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:01","pubTimestamp":1762290110,"startTime":"0","endTime":"0","summary":"BRIEF-Supernus Pharmaceuticals Q3 Product Sales USD 168.5 Million\n\n\nNov 04 (Reuters) - Supernus Pharmaceuticals Q3 operating earnings USD -60.231 million.\n\nQ3 adjusted revenue USD 170 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nPLXF8C50C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SUPN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.supernus.com","stockEarnings":[{"period":"1week","weight":-0.035},{"period":"1month","weight":-0.068},{"period":"3month","weight":-0.0867},{"period":"6month","weight":0.4369},{"period":"1year","weight":0.2487},{"period":"ytd","weight":-0.0292}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0017},{"period":"3month","weight":0.0177},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.0107}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.642857,"avgChangeRate":0.054336},{"month":2,"riseRate":0.461538,"avgChangeRate":-0.017786},{"month":3,"riseRate":0.538462,"avgChangeRate":0.042926},{"month":4,"riseRate":0.615385,"avgChangeRate":0.026873},{"month":5,"riseRate":0.538462,"avgChangeRate":0.048924},{"month":6,"riseRate":0.642857,"avgChangeRate":0.096745},{"month":7,"riseRate":0.642857,"avgChangeRate":0.033873},{"month":8,"riseRate":0.571429,"avgChangeRate":0.016165},{"month":9,"riseRate":0.357143,"avgChangeRate":-0.022786},{"month":10,"riseRate":0.5,"avgChangeRate":-0.001556},{"month":11,"riseRate":0.571429,"avgChangeRate":-0.006005},{"month":12,"riseRate":0.5,"avgChangeRate":-0.005978}],"exchange":"NASDAQ","name":"Supernus Pharmaceuticals","nameEN":"Supernus Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Supernus Pharmaceuticals(SUPN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Supernus Pharmaceuticals(SUPN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Supernus Pharmaceuticals,SUPN,Supernus Pharmaceuticals股票,Supernus Pharmaceuticals股票老虎,Supernus Pharmaceuticals股票老虎国际,Supernus Pharmaceuticals行情,Supernus Pharmaceuticals股票行情,Supernus Pharmaceuticals股价,Supernus Pharmaceuticals股市,Supernus Pharmaceuticals股票价格,Supernus Pharmaceuticals股票交易,Supernus Pharmaceuticals股票购买,Supernus Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Supernus Pharmaceuticals(SUPN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Supernus Pharmaceuticals(SUPN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction